HIMS

HIMS Stock Snaps 3-Day Losing Streak: FDA Adds 8 New Peptide Voters Deemed More Qualified And Less Conflicted

Published: Jul 22, 2026   |  Read Original Article ↗

Article Summary

HOLD
  • Hims & Hers Health Inc. (NYSE: HIMS) rebounded slightly after FDA expanded its peptide advisory panel with eight new voting members ahead of a crucial review of seven unapproved compounds, including BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax and Epitalon, with former FDA official Peter Lurie calling additions considerably more qualified and less conflicted than earlier nominees.
  • Hims & Hers Health's stock rose 0.1% on Tuesday after a three-day losing streak but remains on track for its worst month since February.
  • The panel will evaluate seven compounds for possible inclusion on the Section 503A Bulks List, which could give certain licensed pharmacies a clearer legal route to compound the substances for individual patients.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts. See Plans
Growth Stock Metric Rating
HIMS Rating
62.8
HOLD

Growth Stock Scoring Breakdown

METRIC VALUE WEIGHT ANALYSIS
Sales Growth TTM ? 32.8% 25% 85.0 ptsExcellent (32.8%) - Strong growth
EPS Growth Next 5Y ? 15.2% 25% 50.0 ptsMeets Minimum (15.2%) - Passes screener
Target Price Upside ? 8.3% 20% 10.0 ptsNear/At Target (8.3%) - Target: $29.85 vs Current: $32.55
Gross Margin % ? 57.5% 15% 80.0 ptsVery Healthy (57.5%) - High-quality margins
Drawdown from 52-Wk High ? -53.8% 15% 100.0 ptsDeep Discount (-53.8%) - Best entry opportunity
Disclaimer: This rating is for informational purposes only and is not financial advice. All data sourced from Finviz. Always conduct your own research and consult with a financial advisor before making investment decisions. Past performance does not guarantee future results.

HIMS - Daily Chart

Loading chart data...
Powered by Finviz & ApexCharts

About HIMS

Healthcare Drug Manufacturers - Specialty & Generic 2,442 employees San Francisco, CA, United States
  • Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally.
  • The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
  • It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers.
  • Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services.
  • Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health.
  • The company offers its products through retail partnerships, in stores, and online.
  • Hims & Hers Health, Inc. is based in San Francisco, California.
Get BUY-rated growth stocks delivered after market close.